Subtype
Malignant Glioma
CI-CAN-00003164Explore in graph →
589 active trials3 approved drugs67 evidence items
- NCIt
- C4822
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003164Explore in graph →
Clinical trials
2,053 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (325)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00337883 | A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme) | completed | Phase 2 | 110 | Genentech, Inc.INDUSTRY | 0 | Mar 4, 2014 | clinicaltrials |
| NCT00575887 | Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma | completed | Phase 2 | 25 | Marmara UniversityOTHER | 1 | Dec 20, 2013 | clinicaltrials |
| NCT00921167 |
| A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas |
| completed |
| Phase 2 |
| 32 |
| Clinical Research Center for Solid Tumor, KoreaOTHER |
| 1 |
| Dec 4, 2013 |
| clinicaltrials |
| NCT00431561 | Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma | completed | Phase 2 | 141 | Isarna Therapeutics GmbHINDUSTRY | 6 | Dec 3, 2013 | clinicaltrials |
| NCT00919737 | Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 24 | NobelpharmaINDUSTRY | 1 | Oct 30, 2013 | clinicaltrials |
| NCT00953121 | Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG) | completed | Phase 2 | 104 | Annick DesjardinsOTHER | 1 | Sep 16, 2013 | clinicaltrials |
| NCT00305656 | AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Aug 22, 2013 | clinicaltrials |
| NCT00612430 | Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | completed | Phase 2 | 59 | Duke UniversityOTHER | 1 | Aug 12, 2013 | clinicaltrials |
| NCT00672243 | Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | completed | Phase 2 | 32 | Duke UniversityOTHER | 1 | Aug 7, 2013 | clinicaltrials |
| NCT00039494 | Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors | completed | Phase 2 | 171 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00016328 | CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00014170 | Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00613028 | Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | completed | Phase 2 | 23 | Duke UniversityOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00717197 | Study of Capecitabine to Treat Recurrent High Grade Gliomas | completed | Phase 2 | 30 | University of FloridaOTHER | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00870181 | ADV-TK Improves Outcome of Recurrent High-Grade Glioma(HGG-01) | completed | Phase 2 | 47 | Huazhong University of Science and TechnologyOTHER | 1 | Jun 25, 2013 | clinicaltrials |
| NCT00597493 | Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM | completed | Phase 2 | 32 | Duke UniversityOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00939991 | Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 48 | Katy PetersOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00501891 | Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma | completed | Phase 2 | 32 | Duke UniversityOTHER | 1 | May 27, 2013 | clinicaltrials |
| NCT00612339 | Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | completed | Phase 2 | 41 | Duke UniversityOTHER | 1 | May 27, 2013 | clinicaltrials |
| NCT00671970 | Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) | completed | Phase 2 | 57 | Duke UniversityOTHER | 1 | May 13, 2013 | clinicaltrials |
| NCT00058097 | Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2013 | clinicaltrials |
| NCT00615927 | Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) | completed | Phase 2 | 64 | Duke UniversityOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01100177 | Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients | completed | Phase 2 | 12 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Mar 11, 2013 | clinicaltrials |
| NCT00354913 | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | completed | Phase 2 | 21 | Duke UniversityOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00190424 | Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma | completed | Phase 2 | 80 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 13, 2012 | clinicaltrials |
| NCT00606008 | A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 19, 2012 | clinicaltrials |
| NCT01200134 | HYPONCO - Hypoxia in Brain Tumors(HYPONCO) | completed | Phase 2 | 39 | University Hospital, CaenOTHER | 1 | Nov 19, 2012 | clinicaltrials |
| NCT00409214 | Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma | completed | Phase 2 | 18 | Light Sciences OncologyINDUSTRY | 1 | Nov 16, 2012 | clinicaltrials |
| NCT01251484 | BIBF 1120 in Recurrent Glioblastoma Multiforme | completed | Phase 2 | 25 | Ulrik LassenOTHER | 1 | Oct 4, 2012 | clinicaltrials |
| NCT00624728 | Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)(GLIO-TEP) | completed | Phase 1 / Phase 2 | 21 | University Hospital, BordeauxOTHER | 1 | May 4, 2012 | clinicaltrials |
| NCT01285414 | Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 5 | Myrexis Inc.INDUSTRY | 1 | Apr 11, 2012 | clinicaltrials |
| NCT00412542 | Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas | completed | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT00036569 | A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Feb 13, 2012 | clinicaltrials |
| NCT00071539 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | completed | Phase 2 | 56 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | Jan 20, 2012 | clinicaltrials |
| NCT00504660 | 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients | completed | Phase 2 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 11, 2012 | clinicaltrials |
| NCT00817284 | Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM) | completed | Phase 2 | 60 | Ulrik LassenOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00892931 | Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | Myrexis Inc.INDUSTRY | 1 | Oct 14, 2011 | clinicaltrials |
| NCT00715013 | Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma | completed | Phase 1 / Phase 2 | 9 | University of ZurichOTHER | 0 | Sep 15, 2011 | clinicaltrials |
| NCT00600054 | Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma | completed | Phase 2 | 44 | YM BioSciencesINDUSTRY | 3 | Jul 6, 2011 | clinicaltrials |
| NCT00041587 | Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 / Phase 2 | 80 | INSYS Therapeutics IncINDUSTRY | 3 | Jun 6, 2011 | clinicaltrials |
| NCT00104091 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | completed | Phase 2 | 56 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | May 23, 2011 | clinicaltrials |
| NCT00238797 | A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme | completed | Phase 2 | 36 | AstraZenecaINDUSTRY | 1 | Jan 21, 2011 | clinicaltrials |
| NCT01242566 | Temozolomide in Elderly Patients With KPS < 70(TAG) | completed | Phase 2 | 70 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 17, 2010 | clinicaltrials |
| NCT00800917 | A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme | completed | Phase 2 | 12 | Rigshospitalet, DenmarkOTHER | 1 | Jun 2, 2010 | clinicaltrials |
| NCT00165477 | Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00283556 | High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma | completed | Phase 1 / Phase 2 | 30 | Kentuckiana Cancer InstituteOTHER | 1 | Jan 20, 2010 | clinicaltrials |
| NCT00944801 | Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 63 | University of RegensburgOTHER | 1 | Jul 23, 2009 | clinicaltrials |
| NCT00032903 | This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma. | completed | Phase 1 / Phase 2 | 59 | Sigma-Tau Research, Inc.INDUSTRY | 1 | Jun 3, 2009 | clinicaltrials |
| NCT00115440 | BNCT to Treat Glioma That Has Progressed Following Radiotherapy | completed | Phase 1 / Phase 2 | 22 | Boneca CorporationINDUSTRY | 1 | Jan 28, 2009 | clinicaltrials |
| NCT00306618 | Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma | completed | Phase 2 | 27 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Dec 10, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Mar 4, 2014source: clinicaltrials